Presented for research literature review only Vesel E et al

The beneficiary is at least eighteen (18) years of age and has a BMI greater than or equal to thirty-five (35) at the time of initiation of GLP-1 therapy, or The beneficiary is at least eighteen (18) years of age and has a BMI greater than or equal to thirty (30) at the time of initiating GLP-1 therapy with a diagnosis of one or more of the following: Heart failure with preserved ejection fraction, uncontrolled hypertension (defined as systolic blood pressure above 140 mm Hg or diastolic blood pressure above 90 mm Hg, despite concurrent treatment with two antihypertensive medications , or chronic kidney disease stage 3a or above, or The beneficiary is at least eighteen (18) years of age and has a BMI greater than or equal to twenty-seven (27) at the time of initiating GLP-1 therapy with a diagnosis of one or more of the following: Pre-diabetes (as defined by American Diabetes Association guidelines), previous myocardial infarction, previous stroke, or symptomatic peripheral artery disease

This includes: Anorexia nervosa, past or present Restrictive eating patterns with medical instability or significant fear of eating Active severe restriction, even if it does not carry a formal diagnosis Binge eating disorder For binge eating disorder , the evidence is more nuanced
BPC-157 + TB4-Fragmentis a premium research-grade peptide blend
Acta Scientific Medical Sciences, 8 (10), 62-67